



1	SOLID HISTORY	10 Years of R&D and Robust Intellectual Portfolio <ul style="list-style-type: none"> ▪ Vaxil has 6 patents granted, with an additional 10 patents pending ▪ Recently obtained (July 2016) first US patent in addition to FDA Orphan Status
2	STRONG TEAM	Strong Team of Highly Specialized Scientists <ul style="list-style-type: none"> ▪ Supported by 6 PhD scientists educated at Weizmann, MIT, U of T, Stanford ▪ Team has track record of multiple exits, IPOs, licensing deals with big-pharma
3	IMMUNO PIPELINE	VaxHit™ Platform Generating Proprietary Neo-Antigen Immunotherapies <ul style="list-style-type: none"> ▪ Immucin™: 1st product from VaxHit™, Phase-I/II complete & Orphan Status ▪ Presenting and targeting high-profile cancer antigens in novel manner
4	ANTIBODY PLATFORM	1st Ever Signal-Peptide Specific Antibodies - SPmAb™ <ul style="list-style-type: none"> ▪ Developed the first ever signal peptide specific antibodies using ▪ For use as companion diagnostics and therapy via novel MOA
5	TB VACCINE	VaxHit™ Platform Utilized for Production of Anti-Infective Products <ul style="list-style-type: none"> ▪ Vaccines with superior immunity demonstrated in over 200 patients samples ▪ Currently pursuing partnerships for these products
6	VALUATION	Compelling Valuation with Clean Structure Listed on TSX-Venture <ul style="list-style-type: none"> ▪ Ground level valuation at \$6M CAD considering \$12M spent on R&D 10+ years ▪ No debt and 47M shares outstanding
7	EXCITING FUTURE	Aggressively Advancing to Phase-II and Significant Future Milestones <ul style="list-style-type: none"> ▪ Pursuing optimal Phase-II to include a larger number of patients ▪ Concurrently testing combination therapies and collaborations



Vaxil – Novel Immunotherapy Platform

